- Home
- FUSE vs CVM Comparison
FUSE vs CVM Comparison
Compare FUSE & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FUSE | CVM |
|---|---|---|
| Founded | 2013 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.2M | 41.2M |
| IPO Year | N/A | 1987 |
Fundamental Metrics
Financial Performance| Metric | FUSE | CVM |
|---|---|---|
| Price | $1.73 | $4.86 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 10.9M | 78.9K |
| Earning Date | 06-05-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,949,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.87 | N/A |
| 52 Week Low | $1.45 | $1.98 |
| 52 Week High | $25.00 | $20.41 |
Technical Indicators
Market Signals| Indicator | FUSE | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 45.91 | 44.61 |
| Support Level | $1.65 | $4.73 |
| Resistance Level | $2.13 | $5.49 |
| Average True Range (ATR) | 0.35 | 0.53 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 6.84 | 22.01 |
Price Performance
Historical ComparisonAbout FUSE Fusemachines Inc.
Fusemachines Inc is a provider of enterprise AI products and solutions. The company provides good quality AI education in underserved communities and helping organizations achieve their full potential with AI. The products of the company include AI Studio, Answer Gen, GenAI Engines, and others.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.